Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

Abstract Objective To determine whether serum creatine kinase activity (CK) and serum creatinine concentration (Crn) are prognostic and predictive biomarkers for disease severity, disease progression, and nusinersen treatment effects in adult patients with 5q‐associated spinal muscular atrophy (SMA)...

Full description

Bibliographic Details
Main Authors:	Maren Freigang, Claudia D. Wurster, Tim Hagenacker, Benjamin Stolte, Markus Weiler, Christoph Kamm, Olivia Schreiber‐Katz, Alma Osmanovic, Susanne Petri, Alexander Kowski, Thomas Meyer, Jan C. Koch, Isabell Cordts, Marcus Deschauer, Paul Lingor, Elisa Aust, Daniel Petzold, Albert C. Ludolph, Björn Falkenburger, Andreas Hermann, René Günther
Format:	Article
Language:	English
Published:	Wiley 2021-05-01
Series:	Annals of Clinical and Translational Neurology
Online Access:	https://doi.org/10.1002/acn3.51340

Similar Items

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
by: Alma Osmanovic, et al.
Published: (2021-03-01)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
by: Maren Freigang, et al.
Published: (2021-07-01)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
by: Isabell Cordts, et al.
Published: (2020-01-01)

Nusinersen for spinal muscular atrophy
by: Claudia D. Wurster, et al.
Published: (2018-03-01)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
by: Alma Osmanovic, et al.
Published: (2021-03-01)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
by: Claudia D. Wurster, et al.
Published: (2019-11-01)

Quality of Life in SMA Patients Under Treatment With Nusinersen
by: Lucas Mix, et al.
Published: (2021-03-01)

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
by: Claudia D. Wurster, et al.
Published: (2019-05-01)

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
by: René Günther, et al.
Published: (2019-11-01)

Studies in the physiology of creatine and creatinine
by: Shapiro, B G
Published: (2020)

Creatine and creatinine, with special reference to the creatinine coefficient in pulmonary tuberculosis
by: Galloway, Robert Menzies
Published: (1925)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
by: Benjamin Stolte, et al.
Published: (2018-10-01)

The action of cyanamid and its relation to creatin and creatinin
by: Allinson, Morris Jonathan Carl, 1912-
Published: (2014)

Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen
by: Svenja Brakemeier, et al.
Published: (2021-09-01)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
by: Andreas Totzeck, et al.
Published: (2019-10-01)

Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen
by: Stefan Gingele, et al.
Published: (2019-07-01)

Development of Ratiometric Fluorescent Biosensors for the Determination of Creatine and Creatinine in Urine
by: Hong Dinh Duong, et al.
Published: (2017-11-01)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
by: Kathrin Kizina, et al.
Published: (2019-11-01)

GC-MS Studies on Derivatization of Creatinine and Creatine by BSTFA and Their Measurement in Human Urine
by: Olga Begou, et al.
Published: (2021-05-01)

Searching for a better formulation to enhance muscle bioenergetics: A randomized controlled trial of creatine nitrate plus creatinine vs. creatine nitrate vs. creatine monohydrate in healthy men
by: Sergej M. Ostojic, et al.
Published: (2019-11-01)

Nusinersen and spinal muscular atrophies: Where are we in 2020?
by: Satish V Khadilkar, et al.
Published: (2020-01-01)

Spinal muscular atrophy 5Q – Treatment with nusinersen
by: Antonio Silvinato, et al.

Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular Atrophy
by: Zhu Xiaoying
Published: (2021-01-01)

Changes in serum creatinine, uric acid, creatine kinase, and glomerular filtration rate in street runners
by: Anderson Pontes Morales, et al.
Published: (2013-01-01)

The efficacy and safety of nusinersen within the expanded access program in Russia
by: S. B. Artemieva, et al.
Published: (2020-12-01)

Comparison of time-dependent effects of (+)-methamphetamine or forced swim on monoamines, corticosterone, glucose, creatine, and creatinine in rats
by: Gudelsky Gary A, et al.
Published: (2008-05-01)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
by: Maria Carmela Pera, et al.
Published: (2021-08-01)

Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
by: Fahad Alsohime, et al.
Published: (2020-01-01)

Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
by: Morten Magelssen, et al.
Published: (2021-05-01)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
by: Praveen Thokala, et al.
Published: (2020-10-01)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
by: Bakri Elsheikh, et al.
Published: (2021-04-01)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
by: Bakri Elsheikh, et al.
Published: (2021-05-01)

Serum creatine, creatinine and total homocysteine concentration-time profiles after a single oral dose of guanidinoacetic acid in humans
by: Sergej M. Ostojic, et al.
Published: (2014-01-01)

Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives
by: Pavel Schischlevskij, et al.
Published: (2021-06-01)

A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany
by: Tara Peseschkian, et al.
Published: (2021-03-01)

Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy
by: Meaghann S. Weaver, et al.
Published: (2021-07-01)

Treatment with nusinersen in a girl with spinal muscular atrophy type 1 - Case report
by: Tanja Loboda, et al.
Published: (2020-07-01)

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients
by: Silvia Bonanno, et al.
Published: (2020-01-01)

Changes in skeletal and cardiac muscle caused by prolonged protein-calorie malnutrition in relation to serum creatine kinase activity and the urinary excretion of creatinine
by: Reindorp, Suzanne
Published: (1970)

Nusinersen: uma mudança de paradigma na evolução natural da atrofia muscular espinhal?
by: Francisco da Cruz Pontes Martins da Costa
Published: (2019)